Verquvo (vericiguat) / Bayer, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   27 Trials   27 Trials   1089 News 


«12...4567891011121314...1516»
  • ||||||||||  Clinical, Review, Journal:  Women and Diabetes: Preventing Heart Disease in a New Era of Therapies. (Pubmed Central) -  Nov 17, 2021   
    Recent studies highlight the need for better management of diabetes in women that can be pursued and achieved in light of recent results from randomised controlled trials demonstrating evidence of the benefits of new therapeutic strategies in improving cardiovascular outcomes and quality of life of women covering the entire cardiovascular continuum. This review critically discusses the multiple benefits for women of new pharmacological treatments, such as glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter type 2 inhibitors (SGLT2i), proprotein convertase subtilisin/kexin type 9 inhibitors, inclisiran, icosapent ethyl and bempedoic acid in preventing cardiovascular events, and treatments, such as angiotensin receptor neprilysin inhibitors, SGLT2i, vericiguat and omecamtiv mecarbil, for preventing heart failure.
  • ||||||||||  Journal:  European Society of Cardiology (ESC) Congress 2021 (August 27-30, 2021 - Virtual Meeting). (Pubmed Central) -  Nov 6, 2021   
    This review critically discusses the multiple benefits for women of new pharmacological treatments, such as glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter type 2 inhibitors (SGLT2i), proprotein convertase subtilisin/kexin type 9 inhibitors, inclisiran, icosapent ethyl and bempedoic acid in preventing cardiovascular events, and treatments, such as angiotensin receptor neprilysin inhibitors, SGLT2i, vericiguat and omecamtiv mecarbil, for preventing heart failure. The 2021 Congress of the European Society of Cardiology (ESC) was again held as a digital experience, providing poster and oral sessions highlighting the latest developments in cardiovascular science, including therapeutics for a range of related conditions and updates on ongoing trials, as well as guideline updates.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Review, Journal:  Vericiguat: First Approval. (Pubmed Central) -  Nov 4, 2021   
    Based on the results of the phase III VICTORIA trial vericiguat was recently approved in the USA for risk reduction in patients with heart failure and ejection fraction < 45%. This article summarizes the milestones in the development of vericiguat leading to this first approval.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier, Procoralan (ivabradine) / Amgen, Servier, Ono Pharma
    Review, Journal:  The 'diamond' approach to personalized drug treatment of heart failure with reduced ejection fraction. (Pubmed Central) -  Oct 30, 2021   
    Most importantly, we propose the HF diamond approach to express the necessity of conjunction of therapies. Different from the current guidelines, we suggest to use the diamond approach in an early and comprehensive manner at the beginning of ventricular remodeling in HFrEF to prevent further deterioration of HF and maximize the prognosis of patients.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Review, Journal:  Soluble Guanylate Cyclase Stimulators in Heart Failure. (Pubmed Central) -  Oct 22, 2021   
    We concluded that soluble guanylate cyclase stimulators have significant benefits in reducing hospitalizations in patients with heart failure with reduced ejection fraction that are at high risk of cardiovascular events. There appears to be no benefit of these drugs in patients with heart failure with preserved ejection fraction.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier
    Review, Journal:  Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy. (Pubmed Central) -  Oct 14, 2021   
    These new comprehensive data have led to a remarkable change in the medical therapy paradigm in the setting of HFrEF. This article will review the pivotal studies involving these novel agents and present a suggestive paradigm of pharmacological therapy representing the 2021 European Society of Cardiology (ESC) guidelines for the treatment of chronic HFrEF.
  • ||||||||||  Journal:  Soluble guanylate cyclase stimulators and activators: Past, present and future. (Pubmed Central) -  Oct 3, 2021   
    Here we highlight the discovery and development of sGC stimulators and sGC activators, their unique modes of action, their preclinical characteristics and the clinical studies. In future, we expect to see more sGC agonists in new indications, reflecting their unique therapeutic potential.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal:  Vericiguat. (Pubmed Central) -  Oct 1, 2021   
    A better evaluation of HF severity might be an important determinant to guide the use of vericiguat among the available therapies. No abstract available
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, omecamtiv mecarbil (AMG 423) / Amgen, Servier
    Journal:  Filling the gaps in guideline-directed care. (Pubmed Central) -  Sep 26, 2021   
    Addressing heart failure is a team effort, and such teams need overlapping expertise, innovative approaches, and resources that support and sustain their efforts. Team members should familiarize themselves with the American College of Cardiology 2021 Update to the 2017 Expert Consensus Decision Pathway as a means to offer the best care to the patients that they serve.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), Tepmetko (tepotinib) / EMD Serono, Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
    Journal:  New Drugs. (Pubmed Central) -  Sep 5, 2021   
    Following that, waiting periods of 3 months (for ischemic cardiomyopathy) and 6 months (for non-ischemic cardiomyopathy) may be required to allow adequate reverse remodeling before re-evaluating for ICD implantation. The manuscript contains description of three new medications (vericiguat, tepotinib, tivozanib) which were approved by the US Federal Drug Administration in 2021 and can be used in older populations.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Preclinical, Journal:  Soluble Guanylate Cyclase Stimulator Vericiguat Enhances Long-Term Memory in Rats without Altering Cerebral Blood Volume. (Pubmed Central) -  Aug 28, 2021   
    Vericiguat successfully enhanced long-term memory and increased hippocampal plasticity via enhanced translocation of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors to the cell membrane, while blood pressure and cerebral blood volume were unaltered. Although the memory enhancing effects in this study are likely due to peripheral effects on the cerebral microvasculature, sGC stimulation may provide a new therapeutic strategy for treating VCI, especially when BBB integrity is reduced.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Review, Journal:  Vericiguat for Heart Failure with Reduced Ejection Fraction. (Pubmed Central) -  Aug 27, 2021   
    Clinical trials have suggested the benefit of vericiguat in patients with high-risk HF; in particular, a lower incidence of death from cardiovascular causes or HF hospitalization. Adding vericiguat may be considered in individual patients with HF, and reduced left ventricular ejection fraction (HFrEF) particularly those at higher risk of HF hospitalization.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Procoralan (ivabradine) / Amgen, Servier, Ono Pharma
    44 - Unintended Side Effects: Polypharmacy, Adherence, and Financial Toxicity of Evolving GDMT for HF (Colorado D) -  Aug 9, 2021 - Abstract #HFSA2021HFSA_483;    
    Unfortunately, patients rarely have discussions with their providers about the complexity and cost of their heart failure medications during the clinical encounters, which often involve complex tradeoffs. This session will highlight the impact that medication complexity and cost have on adherence and heart failure outcomes and provide some pragmatic solutions for dealing with this unintended “toxicity”. 1 CME/NCPD (CNE), CPE, and 1 nursing pharmacology credit; 1 CPE.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Clinical, Journal:  Vericiguat organic nitrates, and heart failure in African Americans. (Pubmed Central) -  Aug 6, 2021   
    A randomized, double-blind, placebo-controlled trial in patients with higher risk HFrEF in which AA were underrepresented found that vericiguat reduced the composite primary outcome of cardiovascular death or first HF hospitalization. In the new era of guideline directed medical therapies of quadruple therapy - hydralazine and isosorbide dinitrate should be preferred over vericiguat in AA with HFrEF.